Abbott to broaden foundation in structural heart therapies with acquisitions
Abbott announced an agreement to purchase Tendyne Holdings for $225 million upfront, plus potential future payments tied to regulatory milestones. Separately, Abbott has provided capital and secured an option to purchase Cephea Valve Technologies. Financial terms were not disclosed. July 30, 2015